Bristol Myers Squibb 3Q Revenues: $11.6 billion (+10%) 3Q Earnings: $1.6 billion (-17%) YTD Revenues: $34.4 billion (+9%) YTD Earnings: $4.6 billion (+350%) Comments: Growth in the quarter was driven by Revlimid, Eliquis, Opdivo and new products Reblozyl, Inrebic, Onureg, Zeposia, Breyanzi, and Abecema. Revlimid sales were $3.3 billion in the quarter, up 11%. Eliquis sales were $2.4 billion, up 15%. Opdivo sales were $1.9 billion, up 7%. Orencia sales were $870 million, up 5%. Pomalyst/Im...